Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners is utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd. Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to achieve this additional milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at BI."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.